Ignite Creation Date:
2024-05-06 @ 5:40 PM
Last Modification Date:
2024-10-26 @ 2:33 PM
Study NCT ID:
NCT05389462
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2022-05-20
Brief Title:
A Study of Mipasetamab Uzoptirine ADCT-601 in Participants With Solid Tumors
Sponsor:
ADC Therapeutics SA
Organization:
ADC Therapeutics SA
Study Overview
Official Title:
A Phase 1b Open-Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics and Antitumor Activity of Mipasetamab Uzoptirine ADCT-601 Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to identify the recommended phase 2 dose RP2D andor the maximum tolerated dose MTD and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-005566-18 | EUDRACT_NUMBER | None | None |